Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-resistant Clinical Isolates of Mycobacterium Tuberculosis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2010 Oct 27

PMID 20974869

Citations 36

Authors

F Brossier

N Veziris

C Truffot-Pernot

V Jarlier

W Sougakoff

Affiliations

Soon will be listed here.

Abstract

Ethionamide (ETH) needs to be activated by the mono-oxygenase EthA, which is regulated by EthR, in order to be active against Mycobacterium tuberculosis. The activated drug targets the enzyme InhA, which is involved in cell wall biosynthesis. Resistance to ETH has been reported to result from various mechanisms, including mutations altering EthA/EthR, InhA and its promoter, the NADH dehydrogenase encoded by ndh, and the MshA enzyme, involved in mycothiol biosynthesis. We searched for such mutations in 87 clinical isolates: 47 ETH-resistant (ETH(r)) isolates, 24 ETH-susceptible (ETH(s)) isolates, and 16 isolates susceptible to ETH but displaying an intermediate proportion of resistant cells (ETH(Sip); defined as ≥1% but <10% resistant cells). In 81% (38/47) of the ETH(r) isolates, we found mutations in ethA, ethR, or inhA or its promoter, which mostly corresponded to new alterations in ethA and ethR. The 9 ETH(r) isolates without a mutation in these three genes (9/47, 19%) had no mutation in ndh, and a single isolate had a mutation in mshA. Of the 16 ETH(Sip) isolates, 7 had a mutation in ethA, 8 had no detectable mutation, and 1 had a mutation in mshA. Finally, of the 24 ETH(s) isolates, 23 had no mutation in the studied genes and 1 displayed a yet unknown mutation in the inhA promoter. Globally, the mechanism of resistance to ETH remained unknown for 19% of the ETH(r) isolates, highlighting the complexity of the mechanisms of ETH resistance in M. tuberculosis.

Citing Articles

Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.

Chand A, Basnet A, Maharjan B, Rai G, Joshi Y, Bhatt L PLoS One. 2024; 19(5):e0301210.

PMID: 38709710 PMC: 11073693. DOI: 10.1371/journal.pone.0301210.

Clustering minimal inhibitory concentration data through Bayesian mixture models: An application to detect resistance mutations.

Grazian C Stat Methods Med Res. 2023; 32(12):2423-2439.

PMID: 37920984 PMC: 10710010. DOI: 10.1177/09622802231211010.

How do Mutations of Mycobacterium Genes Cause Drug Resistance in Tuberculosis?.

Hou K, Jabeen R, Sun L, Wei J Curr Pharm Biotechnol. 2023; 25(6):724-736.

PMID: 37888812 DOI: 10.2174/0113892010257816230920053547.

Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Isolates from Southern Xinjiang, China.

Cao B, Mijiti X, Deng L, Wang Q, Yu J, Anwaierjiang A Infect Drug Resist. 2023; 16:3117-3135.

PMID: 37228658 PMC: 10204763. DOI: 10.2147/IDR.S407525.

A pro-oxidant property of vitamin C to overcome the burden of latent infection: A cross-talk review with Fenton reaction.

Gaglani P, Dwivedi M, Upadhyay T, Kaushal R, Ahmad I, Saeed M Front Cell Infect Microbiol. 2023; 13:1152269.

PMID: 37153159 PMC: 10155705. DOI: 10.3389/fcimb.2023.1152269.

References

Ho Y, Sun Y, Wong S, Lee A . Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2009; 53(9):4010-2. PMC: 2737874. DOI: 10.1128/AAC.00433-09. View

Morlock G, Metchock B, Sikes D, Crawford J, Cooksey R . ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003; 47(12):3799-805. PMC: 296216. DOI: 10.1128/AAC.47.12.3799-3805.2003. View

Baulard A, Betts J, Quan S, McAdam R, Brennan P, Locht C . Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem. 2000; 275(36):28326-31. DOI: 10.1074/jbc.M003744200. View

Jureen P, Werngren J, Toro J, Hoffner S . Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2008; 52(5):1852-4. PMC: 2346646. DOI: 10.1128/AAC.00110-08. View

CANETTI G, Kreis B, THIBIER R, Gay P, Le Lirzin M . [Current data on primary resistance in pulmonary tuberculosis in adults in France. 2d survey of the Centre d'Etudes sur la Resistance Primaire: 1965-1966]. Rev Tuberc Pneumol (Paris). 1967; 31(4):433-74. View

CANETTI G, RIST N, Grosset J . [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris). 1963; 27:217-72. View

Hazbon M, Brimacombe M, Bobadilla Del Valle M, Cavatore M, Guerrero M, Varma-Basil M . Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006; 50(8):2640-9. PMC: 1538650. DOI: 10.1128/AAC.00112-06. View

Vilcheze C, Wang F, Arai M, Hazbon M, Colangeli R, Kremer L . Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med. 2006; 12(9):1027-9. DOI: 10.1038/nm1466. View

Miesel L, Weisbrod T, Marcinkeviciene J, Bittman R, Jacobs Jr W . NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol. 1998; 180(9):2459-67. PMC: 107189. DOI: 10.1128/JB.180.9.2459-2467.1998. View

10.

Zhang Y, Heym B, Allen B, Young D, Cole S . The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992; 358(6387):591-3. DOI: 10.1038/358591a0. View

11.

Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W . Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol. 2006; 44(10):3659-64. PMC: 1594786. DOI: 10.1128/JCM.01054-06. View

12.

Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, Karasulu L . The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001; 345(3):170-4. DOI: 10.1056/NEJM200107193450303. View

13.

Frenois F, Baulard A, Villeret V . Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis. Tuberculosis (Edinb). 2005; 86(2):110-4. DOI: 10.1016/j.tube.2005.07.005. View

14.

Vannelli T, Dykman A, de Montellano P . The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem. 2002; 277(15):12824-9. DOI: 10.1074/jbc.M110751200. View

15.

Argyrou A, Vetting M, Aladegbami B, Blanchard J . Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat Struct Mol Biol. 2006; 13(5):408-13. DOI: 10.1038/nsmb1089. View

16.

Banerjee A, DUBNAU E, Quemard A, Balasubramanian V, Um K, Wilson T . inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994; 263(5144):227-30. DOI: 10.1126/science.8284673. View

17.

Boonaiam S, Chaiprasert A, Prammananan T, Leechawengwongs M . Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin Microbiol Infect. 2009; 16(4):396-9. DOI: 10.1111/j.1469-0691.2009.02838.x. View

18.

Guo H, Seet Q, Denkin S, Parsons L, Zhang Y . Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol. 2006; 55(Pt 11):1527-1531. DOI: 10.1099/jmm.0.46718-0. View

19.

Lee A, Teo A, Wong S . Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2001; 45(7):2157-9. PMC: 90621. DOI: 10.1128/AAC.45.7.2157-2159.2001. View

20.

Ramaswamy S, Reich R, Dou S, Jasperse L, Pan X, Wanger A . Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003; 47(4):1241-50. PMC: 152487. DOI: 10.1128/AAC.47.4.1241-1250.2003. View